Showing posts with label Onglyza. Show all posts
Showing posts with label Onglyza. Show all posts

Friday, September 30, 2011

Do Some Diabetes Drugs Actually Help Your Heart?

September 30th, 2011

written by Michael O’Leary
While looking to find harmful effects of type 2 diabetes drugs on the heart and cardiovascular system, researchers were surprised to find that at least one class of these drugs appear to actually help prevent such effects.

As reported on by MedPage Today at the European Association for the Study of Diabetes meeting last week in Lisbon, Portugal, the researchers found that the class of drugs, called gliptins, were associated with 30 percent reduction in the risk of a major heart-related event, such as a heart attack, compared to diabetes patients who were taking another drug or placebo.

In the wake of the development of heart-related side effects of a cancer drug, called Avandia, last year, the FDA required drug companies to assess the cardiovascular risks of some of the new diabetes drugs.  (Link to published site)

Thursday, September 1, 2011

What’s the Best Drug for Type 2 Diabetes? The Answer Isn’t Simple


September 1st, 2011 by Ryan Luce No Comments
Written by Michael O'Leary

With all the new FDA-approved drugs for type 2 diabetes lately, the question arises, is your current prescription the best for you? With names like Onglyza, Januvia, Byetta, Prandin, Tradjenta, metformin, Amaryl, it can be confusing even to know what to ask your doctor.
In a “best evidence review” published Aug. 30 in MedScape News, Dr. Charles Vega, associate professor in the Department of Family Medicine at the University of California, Irvine, compares the effectiveness and safety of all the medications for type 2 including the newest ones being marketed. At least that’s what he wanted to do. (Link to published site)